Being Patient speaks with President and CEO of Cassava Sciences Remi Barbier about the company's development of an investigational Alzheimer's drug called simufilam, and how scientists are diversifying their approach in finding an effective treatment for the disease. We rely on donations to bring you the latest research on dementia and brain health and to support our amazing team of independent journalists. Please consider donating to support of our mission of giving people impacted by dementia a better resource and connection to experts at the forefront of research. Our audience has grown so rapidly; we have exciting plans for the future to enhance our coverage even further but we need your help. Please consider making a contribution to help fund Being Patient's editorial costs. beingpatient.nationbuilder.com/ --------------------------------------------------------------------------------------------------------------- Stay connected on social media: To catch our Brain Talks live, join our Facebook page: www.facebook.com/beingpatient... To learn more about us, follow us on Instagram: @beingpatientvoices For the latest news on dementia research and lifestyle tips, visit our site: www.beingpatient.com/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related